CancerDrs

Leukemia clinical trials in Virginia

24 actively recruiting leukemia trials at 13 sites across Virginia.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full leukemia transparency page →

Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Virginia:
  • Inova Schar Cancer Institute — Fairfax, Virginia
  • Inova Fairfax Hospital — Falls Church, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …

Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • Inova Fairfax Hospital — Falls Church, Virginia
  • Children's Hospital of The King's Daughters — Norfolk, Virginia
  • Naval Medical Center - Portsmouth — Portsmouth, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AM…

Sponsor: Daiichi Sankyo
NCT ID: NCT06578247
Sites in Virginia:
  • Uva Health System — Charlottesville, Virginia
  • Virginia Commonwealth University (Vcu) Massey Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Sites in Virginia:
  • Virginia Commonwealth University - Massey Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…

Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Virginia:
  • Children's Hospital of Richmond at Virginia Commonwealth University — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in Virginia:
  • University of Virginia Cancer Center ( Site 0040) — Charlottesville, Virginia
  • Inova Schar Cancer Institute ( Site 0015) — Fairfax, Virginia
  • Virginia Commonwealth University (VCU) Medical Center ( Site 0030) — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had be…

Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in Virginia:
  • Blue Ridge Cancer Care (Oncology and Hematology Associates of Southwest Virginia) — Roanoke, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…

Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Virginia:
  • Virginia Cancer Specialists - Fairfax /ID# 268155 — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Virginia:
  • University of Virginia — Charlottesville, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Virginia:
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Virginia:
  • Inova Fairfax Hospital — Falls Church, Virginia
  • Children's Hospital of The King's Daughters — Norfolk, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05554393
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • Inova Schar Cancer Institute — Fairfax, Virginia
  • Inova Fairfax Hospital — Falls Church, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • Inova Fairfax Hospital — Falls Church, Virginia
  • Children's Hospital of The King's Daughters — Norfolk, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
  • Carilion Children's — Roanoke, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…

Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • Inova Fairfax Hospital — Falls Church, Virginia
  • Children's Hospital of The King's Daughters — Norfolk, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • Inova Fairfax Hospital — Falls Church, Virginia
  • Children's Hospital of The King's Daughters — Norfolk, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
  • Carilion Children's — Roanoke, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017…

Sponsor: Juno Therapeutics, a Subsidiary of Celgene
NCT ID: NCT03331198
Sites in Virginia:
  • Local Institution - 0113 — Charlottesville, Virginia
  • Local Institution - 0087 — Richmond, Virginia
  • Virginia Commonwealth University — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of tre…

Sponsor: Loxo Oncology, Inc.
NCT ID: NCT06588478
Sites in Virginia:
  • USO-Virginia Oncology Associates — Hampton, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acu…

Sponsor: Chordia Therapeutics, Inc.
NCT ID: NCT05732103
Sites in Virginia:
  • University of Virginia — Charlottesville, Virginia
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

In this study, tagraxofusp (Tag) is given to patients with CD 123+ myelofibrosis (MF), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) after allogeneic stem cell transplant (HCT) to help prevent relapse. Patients w…

Sponsor: Karen Ballen, MD
NCT ID: NCT05233618
Sites in Virginia:
  • University of Virginia — Charlottesville, Virginia
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Virginia:
  • Chesapeake Regional Medical Center — Chesapeake, Virginia
  • Augusta Health Center for Cancer and Blood Disorders — Fishersville, Virginia
  • Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
  • Bon Secours Westchester Emergency Center — Midlothian, Virginia
  • Bon Secours Saint Francis Medical Center — Midlothian, Virginia
View on ClinicalTrials.gov →
Recruiting Network

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Virginia:
  • University of Virginia — Charlottesville, Virginia
  • Virginia Commonwealth University — Richmond, Virginia
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15